Opolskie Centrum Onkologii Im. Prof. Tadeusza Koszarowskiego W Opolu Samodzielny Publiczny Zaklad Opieki Zdrowotnej — Clinical Trial Site

42 Registered trials

23 Currently recruiting

Organisation

Opolskie Centrum Onkologii Im. Prof. Tadeusza Koszarowskiego W Opolu Samodzielny Publiczny Zaklad Opieki Zdrowotnej

Location

Opole, Poland

Identifier

ORG-100041128

Address

Ul. Katowicka 66a, 45-061, Poland

Departments

2000: Klinika Onkologii z Odcinkiem Dziennym
5703:Oddzial Onkologii Klinicznej z Odcinkiem Dziennym
Clinical Oncology
Clinical Oncology Department with Day Unit
Klinika Onkologii
Klinika Onkologii z Odcinkiem Dziennym
Klinika Onkologii z oddziałem dziennym
NA
Oddzial Onkologii Klinicznej
Oddzial Onkologii Klinicznej z Odcinkiem Dziennym
Oddział Onkologii Klinicznej z Odcinkiem Dziennym
Oncologie
Oncology
Oncology clinic with a day ward
Oncology department

Clinical trials at this site (42)

Search interface

A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5 2026-06-12
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Recruiting

2025-523586-18-00 Non-Small Cell Lung Cancer 5 2026-06-11
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorect… Recruiting

2025-523521-18-00 Metastatic Colorectal Cancer 5 2026-06-09
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5 2026-04-23
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 First line triple-negative breast cancer (TNBC) 5 2026-03-19
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Recruiting

2025-521587-35-00 Metastatic colorectal cancer 5 2026-06-03
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Recruiting

2025-523461-17-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANC 5 2026-06-01
Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Previously Untreated Advanced or Me… Recruiting

2025-523263-37-00 Previously Untreated Advanced or Metastatic Gastric, Ga 10 2026-04-08
Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met… Recruiting

2025-523224-45-00 Untreated, Unresectable or Metastatic Colorectal Cancer 10 2026-03-30
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Breast cancer 10 2025-11-11
A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Breast Cancer: triple negative breast cancer (TNBC) and 5 2025-11-10
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Hormone Receptor-Positive, HER2-Negative Advanced/Metas 5 2025-11-10
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant… Recruiting

2024-511652-40-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-02-05
Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting

2024-513853-66-00 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or 5 2025-02-04
Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc… Recruiting

2024-513852-13-00 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic 5 2025-01-20
Sacubitril/Valsartan in prevention of heart damage during breast cancer treatment Recruiting

2024-517804-12-00 Heart failure – post-anthracycline cardiomyopathy 5 2024-04-17
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting

2022-500967-11-00 Previously Untreated Metastatic or Unresectable Melanom 5 2023-07-06
A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting

2023-504888-16-00 Patients with Human Epidermal Growth Factor Receptor 2 9 2020-10-05
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Ended

2024-517422-25-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-05-22